Vamil Divan - Latest News on Equity Research Analyst - Benzinga

SPY—QQQ707.87−0.27%BTC/USD—DIA—GLD—TLT80.06+0.01%

Vamil Divan

Vamil Divan is a senior equity research analyst known for his coverage of pharmaceutical and biotechnology companies. He has extensive experience evaluating drug pipelines, market trends, and corporate strategies within the healthcare sector. Divan's research is widely followed by institutional investors for its detailed analysis and industry expertise.

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential

Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential

Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'

Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'

Vamil Divan Recent News

Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Credit Suisse Downgrades AbbVie On Humira Competitive Concerns

Credit Suisse Downgrades AbbVie On Humira Competitive Concerns

Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote

Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade

Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'

Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'

Credit Suisse Upgrades Teva After Job Cuts Announced

Credit Suisse Upgrades Teva After Job Cuts Announced

Could The Street Be Underappreciating The Ironwood Pharma Pipeline?

Could The Street Be Underappreciating The Ironwood Pharma Pipeline?

7 Catalysts For Eli Lilly Over The Next Year

7 Catalysts For Eli Lilly Over The Next Year

Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Analyst Prescribes Neutral Rating For Pfizer Shares

Analyst Prescribes Neutral Rating For Pfizer Shares

Analyst Wonders If AstraZeneca's Soriot Would Be A Fit At Teva

Analyst Wonders If AstraZeneca's Soriot Would Be A Fit At Teva

The Street May Be Underappreciating Alder Biopharma's Phase 3 Data

The Street May Be Underappreciating Alder Biopharma's Phase 3 Data

A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse

Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision

Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision

Teva Pharmaceuticals Could Be Poised For A Turnaround

Teva Pharmaceuticals Could Be Poised For A Turnaround

AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside

AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside

Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target

Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target